Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families

Molecular Genetics and Metabolism

Volumn 102, Issue 1, 2011, Pages 82-90

  Hietala, Maria ^a   Henningson, Maria ^a   Törngren, Therese ^a   Olsson, Håkan ^a   Jernström, Helena ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Androgen receptor polymorphisms; Androgens; BRCA; Oral contraceptives; Premenopausal women

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIONE; BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; ARTICLE; BODY CONSTITUTION; BREAST CANCER; CAG REPEAT; CANCER RISK; DNA STRUCTURE; FAMILY STUDY; FEMALE; GENE CLUSTER; GENE MUTATION; GENOTYPE; GGC REPEAT; HAPLOTYPE; HUMAN; IN VIVO STUDY; MENSTRUAL CYCLE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANDROGENS; BASE SEQUENCE; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC MARKERS; HAPLOTYPES; HUMANS; MICROSATELLITE REPEATS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ANDROGEN; RISK FACTORS; YOUNG ADULT;

EID: 78650912356     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.09.006     Document Type: Article

References (41)

1. Karrer-Voegeli S., Rey F., Reymond M.J., Meuwly J.Y., Gaillard R.C., Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore) 2009, 88:32-45.
2. Stanczyk F.Z. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract. Res. Clin. Endocrinol. Metab. 2006, 20:177-191.
3. Schover L.R. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil. Steril. 2008, 90:129-140.
4. Somboonporn W., Davis S.R. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr. Rev. 2004, 25:374-388.
5. Labrie F., Luu-The V., Labrie C., Belanger A., Simard J., Lin S.X., Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 2003, 24:152-182.
6. Micheli A., Muti P., Secreto G., Krogh V., Meneghini E., Venturelli E., Sieri S., Pala V., Berrino F. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int. J. Cancer 2004, 112:312-318.
7. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mesquita H.B., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils C.H., Gonzalez C.A., Gurrea A.B., Critselis E., Khaw K.T., Krogh V., Lahmann P.H., Nagel G., Olsen A., Onland-Moret N.C., Overvad K., Palli D., Panico S., Peeters P., Quiros J.R., Roddam A., Thiebaut A., Tjonneland A., Chirlaque M.D., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2005, 97:755-765.
8. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002, 94:606-616.
9. Missmer S.A., Eliassen A.H., Barbieri R.L., Hankinson S.E. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 2004, 96:1856-1865.
10. Zeleniuch-Jacquotte A., Bruning P.F., Bonfrer J.M., Koenig K.L., Shore R.E., Kim M.Y., Pasternack B.S., Toniolo P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am. J. Epidemiol. 1997, 145:1030-1038.
11. Dimitrakakis C., Bondy C. Androgens and the breast. Breast Cancer Res. 2009, 11:212.
12. Birrell S.N., Hall R.E., Tilley W.D. Role of the androgen receptor in human breast cancer. J. Mammary Gland Biol. Neoplasia 1998, 3:95-103.
13. Yu H., Shu X.O., Li B.D., Dai Q., Gao Y.T., Jin F., Zheng W. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol. Biomark. Prev. 2003, 12:1067-1073.
14. The National Board of Health And Welfare, Cancer Incidence In Sweden 2008, Stockholm, Sweden, 2009.
15. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004, 4:665-676.
16. Lacroix M., Leclercq G. The "portrait" of hereditary breast cancer. Breast Cancer Res. Treat. 2005, 89:297-304.
17. Dumitrescu R.G., Cotarla I. Understanding breast cancer risk-where do we stand in 2005? J. Cell. Mol. Med. 2005, 9:208-221.
18. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
19. Yeh S., Hu Y.C., Rahman M., Lin H.K., Hsu C.L., Ting H.J., Kang H.Y., Chang C. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2000, 97:11256-11261.
20. Suter N.M., Malone K.E., Daling J.R., Doody D.R., Ostrander E.A. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol. Biomark. Prev. 2003, 12:127-135.
21. Westberg L., Baghaei F., Rosmond R., Hellstrand M., Landen M., Jansson M., Holm G., Bjorntorp P., Eriksson E. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J. Clin. Endocrinol. Metab. 2001, 86:2562-2568.
22. Ibanez L., Ong K.K., Mongan N., Jaaskelainen J., Marcos M.V., Hughes I.A., De Zegher F., Dunger D.B. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 2003, 88:3333-3338.
23. Brum I.S., Spritzer P.M., Paris F., Maturana M.A., Audran F., Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J. Soc. Gynecol. Investig. 2005, 12:135-141.
24. Hietala M., Sandberg T., Borg A., Olsson H., Jernström H. Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women. Hum. Reprod. 2007, 22:83-91.
25. Giguere Y., Dewailly E., Brisson J., Ayotte P., Laflamme N., Demers A., Forest V.I., Dodin S., Robert J., Rousseau F. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res. 2001, 61:5869-5874.
26. Liede A., Zhang W., De Leon Matsuda M.L., Tan A., Narod S.A. Cancer Epidemiol. Biomark. Prev. 2003, 12:848-852.
27. Haiman C.A., Brown M., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Kantoff P.W., Hunter D.J. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res. 2002, 62:1045-1049.
28. Rebbeck T.R., Kantoff P.W., Krithivas K., Neuhausen S., Blackwood M.A., Godwin A.K., Daly M.B., Narod S.A., Garber J.E., Lynch H.T., Weber B.L., Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet. 1999, 64:1371-1377.
29. Jernström H.C., Olsson H., Borg Å. Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients. Eur. J. Cancer Prev. 1997, 6:330-340.
30. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996, 347:1713-1727.
31. Jernström H., Sandberg T., Bageman E., Borg A., Olsson H. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J. Cancer 2005, 92:857-866.
32. Narod S.A., Dube M.P., Klijn J., Lubinski J., Lynch H.T., Ghadirian P., Provencher D., Heimdal K., Moller P., Robson M., Offit K., Isaacs C., Weber B., Friedman E., Gershoni-Baruch R., Rennert G., Pasini B., Wagner T., Daly M., Garber J.E., Neuhausen S.L., Ainsworth P., Olsson H., Evans G., Osborne M., Couch F., Foulkes W.D., Warner E., Kim-Sing C., Olopade O., Tung N., Saal H.M., Weitzel J., Merajver S., Gauthier-Villars M., Jernström H., Sun P., Brunet J.S. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 2002, 94:1773-1779.
33. Cox D.G., Blanche H., Pearce C.L., Calle E.E., Colditz G.A., Pike M.C., Albanes D., Allen N.E., Amiano P., Berglund G., Boeing H., Buring J., Burtt N., Canzian F., Chanock S., Clavel-Chapelon F., Feigelson H.S., Freedman M., Haiman C.A., Hankinson S.E., Henderson B.E., Hoover R., Hunter D.J., Kaaks R., Kolonel L., Kraft P., LeMarchand L., Lund E., Palli D., Peeters P.H., Riboli E., Stram D.O., Thun M., Tjonneland A., Trichopoulos D., Yeager M. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006, 8:R54.
34. Lindström S., Wiklund F., Adami H.O., Balter K.A., Adolfsson J., Gronberg H. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res. 2006, 66:11077-11083.
35. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. Am. J. Epidemiol. 2004, 159:319-335.
36. Carr B.R., Breslau N.A., Givens C., Byrd W., Barnett-Hamm C., Marshburn P.B. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J. Clin. Endocrinol. Metab. 1995, 80:1169-1178.
37. Krithivas K., Yurgalevitch S.M., Mohr B.A., Wilcox C.J., Batter S.J., Brown M., Longcope C., McKinlay J.B., Kantoff P.W. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J. Endocrinol. 1999, 162:137-142.
38. Ntais C., Polycarpou A., Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur. J. Endocrinol. 2003, 149:469-477.
39. World Health Organization International Agency on Cancer Hormonal Contraception and Post-menopasual Hormonal Therapy 1999, IARC Press, Lyon, France.
40. Orstavik K.H. Skewed X inactivation in healthy individuals and in different diseases. Acta Paediatr. Suppl. 2006, 95:24-29.
41. Kristiansen M., Knudsen G.P., Maguire P., Margolin S., Pedersen J., Lindblom A., Orstavik K.H. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J. Med. Genet. 2005, 42(11):877-880.